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Abstract: A simple tailor-made protocol to synthesize graphene-based magnetic nanoparticles
(GbMNPs) for nanomedicine is herein reported. Different GbMNPs with very distinctive
physicochemical and toxicological properties were synthesized by adjusting the number of carbon
precursors in the coating of superparamagnetic iron oxide nanoparticles. In vitro tests show
the ability to use these GbMNPs as intelligent and on-demand drug nanocarrier systems for
drug delivery, exhibiting the following features: good colloidal stability, good loading capacity
of the chemotherapeutic drug doxorubicin, high pH-controlled release of the encapsulated drug
(targeting tumour acidic pH conditions), superparamagnetic behaviour and biocompatibility. Due to
their combined properties (i.e., physicochemical, magnetic, and biocompatibility), GbMNPs show
high potentiality to be combined with other biomedical techniques, such as magnetic hyperthermia,
which can represent an enhancement in the treatment of cancer.
Keywords: graphene magnetic nanocomposites; drug delivery; DOX cancer
1. Introduction
In order to overcome magnetic nanoparticle limitations, such as toxicity, self-aggregation and a
low rate of bio-functionalization, many composite magnetic nanosystems have been developed in the
last decade for nanomedicine [1,2]. These nanostructures are usually developed by having a magnetic
core covered with a metal or a non-metal structure, such as gold [3–5], silica [6,7], polymers [8–10],
among others. In general, this core-shell approach allows for, besides protection of the magnetic core,
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the anchoring of various therapeutic drugs or biomolecules for targeted drug delivery, improved
biocompatibility, and prolonged blood circulation half-life [11,12]. Nevertheless, when developed for
drug delivery applications, these systems generally show some limitations, such as a low drug loading
capacity and poor or absence of stimuli-responsive controlled release. Thus, additional efforts are
necessary to add capping scaffolds on the surface of these nanoparticles (e.g., polymers, inorganic
nanoparticles, and biomacromolecules), acting as gatekeepers to enable a controlled drug release
in response to endogenous (i.e., pH, enzymes, among others) or exogenous (i.e., light, temperature
changes, among others) stimuli [13,14]. However, the laborious synthetic protocols proposed to date
hinder the technology transfer to industry. Although the apparent success of nanoparticles developed
and tested at laboratory scale is high, the translation of nanomedicine products to clinical applications
has been limited and slow [15]. In fact, it is estimated that less than 200 nanomedicine products have
been commercialized so far [16]. This phenomenon has been attributed by two main factors: (1) the
inability of current biological models to predict the nanoparticles-cells/organs bio-interactions [16], and
(2) the complex synthetic procedures that just produce a small number of nanomedicine products [17].
Carbon-based magnetic nanoparticles provide high chemical and thermal stability, a large surface
area, biocompatibility and simple functionalization [14,18]. Recent studies, such as those published
by Huang et al., 2016 [13] and Sasikale et al., 2016 [19], have shown that graphene-based materials,
including graphene derivatives such as graphene oxide (GO), can be used as pH-responsive controlled
release systems. This promising capability of graphene-based materials is attributed to pi–pi stacking
interactions allowing the adsorption of a variety of aromatic biomolecules, as well as to the presence of
oxygen and hydrogen-containing surface groups promoting hydrogen bond interactions. However,
the synthesis of magnetic nanoparticles combined with graphene derivatives generally demands
toxic chemicals (e.g., those employed in the Hummers’ method to produce GO [20]), or complex
techniques/methods (e.g., in chemical vapour deposition [21]), often limited to the production of
nanoparticles in a very small scale.
In order to suppress these limitations, a simple procedure to produce graphene-based magnetic
nanoparticles (GbMNPs) is herein presented, which provides different types of GbMNPs by adjusting
the concentration of the carbon precursors. The reported tailor-made protocol allows us to
synthesize smart drug nanocarrier systems for cancer treatment, revealing (i) a high loading of
the chemotherapeutic drug doxorubicin; (ii) a strong pH stimuli-responsive controlled release; (iii) a
high Saturation magnetization (Ms) profile; and (iv) a good biocompatibility.
2. Materials and Methods
2.1. Chemicals
Iron(III) chloride hexahydrate, FeCl3·6H2O (97%), and formaldehyde (37 wt % stabilized with
methanol) were supplied by Panreac. The ammonium hydroxide solution, NH4OH (25 wt % in H2O),
was acquired from Merck. Iron (II) chloride tetrahydrate, FeCl2·4H2O (99 wt %), ethanol
absolute, C2H6O (99.8%), nitric acid, HNO3 (70 wt %), sodium phosphate monobasic, NaH2PO4
(99.0 wt %), sodium phosphate dibasic, Na2HPO4 (99.0 wt %), sodium chloride, NaCl (99.5 wt %),
potassium chloride, KCl (99 wt %), and sodium hydroxide, NaOH (98 wt %), were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Resorcinol (98 wt %) was obtained from Fisher chemicals
(Hampton, NH, USA). Tetraethyl orthosilicate (TEOS) (98 wt %), was supplied from Fluka (St. Louis,
MO, USA). Doxorubicin hydrochloride (DOX) (98 wt %), was purchased from Discovery Fine
Chemicals (Wimborne, UK).
The breast cell line MCF-7 (Michigan Cancer Foundation-7) was acquired from Deutsche
Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Braunschweig, Germany).
Roswell Park Memorial Institute (RPMI) 1640 medium, Hank’s balanced salt solution (HBSS),
fetal bovine serum (FBS), L-glutamine, trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA),
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penicillin/streptomycin solution (100 U·mL−1 and 100 mg·mL−1, respectively) were purchased from
Gibco Invitrogen Life Technologies (Carlsbad, CA, USA).
2.2. Synthesis of GbMNPs
The synthesis procedure of GbMNPs was divided into two stages, i.e., the synthesis of the
magnetic core followed by the graphene-based shell formation, as illustrated in Figure 1.
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The synthesis of the iron oxide core, with a mean diameter of 18 nm, was achieved through
co-precipitation of Fe2+ and Fe3+ (with a molar ratio of 1:2) in a basic solution of ammonium hydroxide
at 55 ◦C, following the procedure described elsewhere [22,23].
Subsequently, the graphene-based shell was accomplished via a one-pot strategy of hydrolysis and
polymerisation of the precursors, i.e., resorcinol, formaldehyde, and TEOS [23,24]. Different GbMNPs,
with different hollow cavities between the shell and the magnetic core, were obtained using different
amounts of these precursors in relation to a fixed mass of the magnetic core, adapting the procedure
described elsewhere (c.f. Table 1) [24]. In brief, a solution containing 0.25 g of iron oxide with
150 mL of ethanol and 50 mL of deionized water was sonicated and transferred into a 250 mL
two-necked round-bottom flask. Then, resorcinol and ammonium hydroxide were added to the
solution and continuously stirred for 1 h at 30 ◦C. Then, the formaldehyde, and TEOS solutions
were added and stirred at 30 ◦C for 6 h. The solution was then heated at 80 ◦C under constant
stirring for another 8 h. The magnetic product resulting from this protocol was washed using
deionized water and absolute ethanol. The resulted magnetic nanostructures were annealed under
a N2 flow (100 cm3·min−1) in a tubular vertical oven at 120 ◦C and 400 ◦C during 60 min at each
temperature, and then at 600 ◦C for 240 min, defining a heating ramp of 2 ◦C·min−1. In the last
step, the silica was removed by etching in a strongly basic NaOH solution (10 mol·L−1, 16 h at room
temperature with stirring), resulting in the graphene-based magnetic nanoparticles (GbMNPs) with a
yolk-shell nanostructure.
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Table 1. The effect of the amount of the precursor resorcinol, formaldehyde, and tetraethyl orthosilicate
(TEOS), over the shell and void thicknesses of GbMNPs.
Material MagneticCore (g)
Resorcinol
(g)
Formaldehyde
(mL) TEOS (mL)
Hollow
Thickness (nm) a
Carbon-Shell
Thickness (nm) a
GbMNP-1 0.25 0.05 0.075 0.10 Not detected 1.41 ± 0.44
GbMNP-2 0.25 0.10 0.150 0.21 0.70 ± 0.30 3.55 ± 1.27
GbMNP-3 0.25 0.20 0.300 0.41 2.07 ± 0.92 7.07 ± 1.88
a Determined by using ImageJ software from HR-STEM images as mean ± standard deviation (n = 60).
2.3. Colloidal Stabilization of GbMNPs
To ensure the hydrophilization of the GbMNPs in aqueous solutions, the graphene-based shells
were chemically functionalized by an acid treatment at mild conditions. In brief, the functionalization
run was conducted in a 250 mL round-bottom flask at 65 ◦C under vigorous magnetic stirring
(C-Mag HS7, IKA, Staufen, Germany). The samples of GbMNPs (5 mg·mL−1) were oxidized with
HNO3 (1 mol·L−1) during 6 h. The activated GbMNPs were washed several times in deionized water
and absolute ethanol. The resulting material was dried overnight at 60 ◦C. The obtained hydrophilic
GbMNPs were used to perform the drug delivery studies with doxorubicin (DOX).
2.4. Characterization of GbMNPs
A wide-angle powder X-ray diffraction (XRD) analysis was carried out in an Expert Pro Philips
X-Ray diffractometer (Malvern Panalytical's, Egham, UK) using a Cu Kα radiation (λ = 1.54 Å).
The Raman spectra of the samples were recorded using a micro-Raman spectrometer apparatus
(Micro-Raman DXR, Thermo Scientific, Waltham, MA, USA) with a 532 nm laser excitation.
A High-Resolution Transmission Electron Microscope (HR-TEM) using a Cs-corrected probe
(ARM 200 CF, Joel, Akishima, Japan) was used to obtain the morphology and microstructure of
the GbMNPs.
The amounts of carbon and magnetic core in the as-synthetized GbMNPs were determined by
thermogravimetric (TG) analysis (STA 449 C Jupiter, Netzsch, Goa, India) and the samples were heated
in air flow from 50 ◦C to 950 ◦C, at 20 ◦C·min−1.
The textural properties of GbMNPs were obtained using N2 adsorption-desorption isotherms at
−196 ◦C (Quantachrome NOVA 4200e, Boynton Beach, FL, USA), as reported elsewhere [23].
The pH at the point of zero charge (pHPZC) of the materials was determined by adapting the
methodology described elsewhere [25].
The magnetic properties of the superparamagnetic core and GbMNPs were explored with
a superconducting quantum interference device (SQUID-VSM) magnetometer (Quantum Design,
San Diego, CA, USA). Hysteresis curves were recorded for magnetic fields between −20 kOe and
20 kOe at 27 ◦C.
2.5. Drug Loading Studies
The drug loading studies were performed by mixing a given amount of DOX (10 to 300 µg·mL−1)
and a fixed amount of GbMNPs (500 µg·mL−1) in a shaking incubator (VWR, Radnor, PA, USA)
during 24 h, in the dark, at room temperature. The resulting GbMNPs encapsulated with the drug
(GbMNPs-DOX) were collected by centrifugation at 15,000 rpm for 30 min, and the supernatant used
to determine the DOX concentration by Ultraviolet-visible spectroscopy (UV–Vis, Bruker, Billerica,
MA, USA) at 480 nm. The drug loading efficiency and drug loading capacity were calculated using
Equations (1) and (2), respectively.
Drug loading efficiency (%) = Inicial concentration of drug−Drug content in the supernatantInicial concentration of drug × 100 (1)
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Drug loading capacity
(
µg·mg−1
)
=
mass of drug loaded
mass of GbMNPs
(2)
2.6. In Vitro pH-Dependent Drug Release and Kinetics Studies
The in vitro pH-dependent drug release of DOX from GbMNPs was performed by using
freeze-dried GbMNPs-DOX samples (2.0 mg) suspended in a phosphate buffer solution (20 mL)
at physiological and acidic pHs (7.4, 6.0 and 4.5) using a shaking incubator at 37 ◦C. The pH-dependent
release of DOX was determined along selected time intervals (0.5, 1, 2, 3, 4, 6, 8, 24, and 48 h),
by collecting samples from the different suspensions of GbMNPs-DOX in phosphate buffers solutions
(pH 4.5, 6.0, and 7.4). The samples were centrifuged, and the supernatant used to monitor the released
DOX at 480 nm in UV–Vis. The drug release kinetics was studied by fitting the drug release data with
zero-order (release independent of concentration), first-order (release dependent of concentration),
Hixson-Crowell (release by dissolution), Higuchi (release by diffusion), and Korsmeyer-Peppas (log
(cumulative drug release) versus log (time) models, by comparing the regression coefficient (R2) values
obtained for the different models.
2.7. In Vitro Biostudies
The developed graphene-based magnetic nanocomposites were investigated to confirm their
biocompatibility and cellular drug-delivery performance.
2.7.1. Cell Culture
The biocompatibility and cellular drug-delivery assays were assessed by using two cell lines,
namely porcine liver primary cells (PLP2) [26], and a human breast tumour cell line (MCF-7). Cell lines
were cultured and maintained prior to the in vitro studies in RPMI-1640 medium containing 10% foetal
bovine serum (FBS), 1% of glutaraldehyde, 1% of penicillin, and 1% of streptomycin, under a humid
atmosphere containing 5% of CO2, at 37 ◦C.
2.7.2. Biocompatibility and Cellular Drug-Delivery Assay
In vitro biocompatibility and cellular drug-delivery studies were assessed by using
sulforhodamine B (SRB) colourimetric assay, as described elsewhere [27]. Briefly, the cell lines were
seeded in 96-well plates, at an initial cell density of 1.0 × 104 cells/well. The biocompatibility
of the GbMNPs was assessed with the primary cell culture, PLP2, using different concentrations
of the free-drug nanocarriers (0.12 to 30.0 µg·mL−1). For the in vitro cellular drug-delivery effect,
the tumour cell line, MCF-7, and primary cell culture, PLP2, were tested and treated with a series of
free DOX and GbMNPs-DOX containing the same amount of free DOX in the tests (0.03, 0.12, 0.47,
1.88, and 7.50 µg (DOX)·mL−1). As blanks, the control wells just containing cells with the cultured
medium were used. For statistical analysis, two individual tissue-culture plates were used, and all the
assays performed in duplicate wells (n = 4). The statistical analysis was performed with the Student’s
t-test with a significance level of p < 0.05, shown as asterisks (*), using Microsoft Office Excel (version
Professional Plus 2013).
3. Results and Discussion
3.1. Synthesis and Characterization of the GbMNPs
The synthesis of the magnetic core and graphene-based shell formation is represented in Figure 1.
HR-TEM micrographs (Figure 2) confirmed the formation of the yolk-shell magnetic nanoparticles,
i.e., the iron oxide cores shelled by a graphene-based layer. As expected, the increment of the amount
of carbon-based precursors (resorcinol, formaldehyde and TEOS) in relation to a fixed mass of the
magnetic core provided an increase of the void and graphene-based shell thickness, as determined
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using the ImageJ software (1.46r, NIH, Bethesda, MD, USA) (Table 1). Thus, three different types of
GbMNPs were synthesized with different hollow cavities and graphene-based shell thicknesses.C 2018, 4, x FOR PEER REVIEW  6 of 15 
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Figure 2. The high-resolution transmission electron microscopy (HR-TEM) bright field images of
samples: (a) GbMNP-1; (b) GbMNP-2; (c) GbMNP-3; and (d) the detail of the magnetic core of iron
oxide covered by a few graphene layers in sample GbMNP-2.
Interestingly, the graphene-based shell thickness increased in the same proportion as the amount
of the precursors used. Thus, by doubling the number of carbon precursors from GbMNP-1 to
GbMNP-2 and GbMNP-3, the shell thickness was successively doubled, as listed in Table 1. HR-TEM
images also allowed for the determination of a lattice spacing of 0.48 nm, indicating that the magnetic
core consisted of iron oxide nanoparticles, as further confirmed by XRD analysis (Figure 3a).
Figure 3a shows the XRD patterns for GbMNPs and the iron oxide material used as the
magnetic core. The 2θ peaks (111), (220), (311), (222), (400), (422), (511), and (440), are ascribed as the
characteristic diffraction peaks of Fe3O4 nanoparticles (JCPDS no. 19-629). Some other peaks were
observed for GbMNP-2 corresponding to (110) and (211) and assigned as metal iron, probably caused
by the reduction of the magnetic core through the thermal annealing procedure (600 ◦C) in an inert
atmosphere [23]. In addition, the presence of the graphene-based material is ascribed by the presence
of a peak at 24.3◦ (002) [28].
Results from the TG analysis are shown in Figure 3b. The first significant weight loss below 150 ◦C
can be ascribed to the removal of water molecules physisorbed on the surface of GbMNPs. The sharp
mass loss observed between 450–600 ◦C is attributed to the combustion of the carbon material [29–33],
revealing mass percentages of the carbon-based shells in the samples of 0.5%, 9.7%, and 18.2% for
GbMNP-1, GbMNP-2, and GbMNP-3, respectively. In addition, the mass of the magnetic core was
calculated as 97.7%, 88.0%, and 77.8% for GbMNP-1, GbMNP-2, and GbMNP-3, respectively.
The Raman spectra of GbMNP-2 and GbMNP-3 are shown in Figure 3c,d, respectively.
Graphene oxide (GO) is suggested in these samples by the D peak at 1350 cm−1, the conventional
G peak at 1582 cm−1 and the 2D peak at 2816 cm−1 [34]. On the other hand, the Raman spectrum
of the sample GbMNP-1 did not show any of these peaks (data not shown), most probably due
to the very low amount of graphene-based shell in this sample (0.5%, determined by TG analysis).
Thus, the GbMNP-1 sample was not considered in the following studies.
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The integrated peak intensity between ID and IG was found as 1.61 for sample GbMNP-2 (using
the new deconvoluted G peak), corresponding to a disordered GO structure [34,35], and 0.43 for t e
sample GbMNP-3 (using the conventional G peak, since no deconvoluted peak was found), indicating
the presence of a defectiv multi-graphitic-layer shell [36], which was also observed by HR-TEM
(Figure 2c). Furthermore, the deconvolution of the conventional G band—in t is c se, the appare t G
band (G pp), brings in evidence the actual G (1546 cm−1) and the D′ (1594 cm−1) bands, which can be
assigned for sample GbMNP-2, but not clearly for sample GbMNP-3. Interestingly, the D′ band was
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reported by Kaniyoor and Ramaprabhu [37] as evidence of the presence of a few layers of wrinkled
graphene-based (FlwG) structures, which is in line with the observed shell nanostructure found in
GbMNP-2 (cf. Figure 2d).
Dynamic light scattering (DLS) measurements (Figure 3d,e) show that the average hydrodynamic
diameter of the samples increased with the increment of the carbon precursors.
The main textural properties of the synthesized GbMNPs are given in Table 2. Specific surface
areas (SBET) of 156 and 245 m2·g−1 were determined for the GbMNP-2 and GbMNP-3 materials,
respectively. These relatively high surface areas, in comparison with that of bare magnetic nanoparticles
(56 m2·g−1), are attributed to the graphene-based shell in the GbMNPs structure, the SBET increasing
with the shell thickness. The analysis of the Vmicro/Vtotal ratios (0.041 and 0.105 for GbMNP-2
and GbMNP-3, respectively), reveals that the samples mainly contain mesopores. In addition,
the average pore diameter of GbMNP-3 is lower than that of GbMNP-2 (5.4 and 8.2 nm, respectively).
This phenomenon can be related to the increment of the thickness of the graphene-based shell
between GbMNPs-2 and GbMNPs-3, which can lead to a denser and more microporous nanostructure.
Overall, the GbMNPs samples, in comparison with uncoated magnetite, exhibit larger surface
area and mesoporous nature, which are relevant characteristics for drug delivery applications,
i.e., the encapsulation, transport, and release of biomolecules [23].
Table 2. The textural properties of the synthesized materials: specific surface area (SBET),
non-microporous surface area (Smeso), micropore volume (Vmicro), total pore volume (Vtotal),
ratio between micropore and total pore volume (Vmicro/Vtotal) and average pore diameter (daverage).
Material SBET(m2·g−1)
Smeso
(m2·g−1)
Vmicro
(cm3·g−1)
V total
(cm3·g−1) Vmicro/V total
daverage
(nm)
GbMNP-2 156 123 0.013 0.318 0.041 8.2
GbMNP-3 245 160 0.035 0.333 0.105 5.4
The magnetic hysteresis curves acquired for iron oxide nanoparticles and GbMNPs are shown
in Figure 4. The determined magnetic properties of these samples are listed in Table 3. Iron oxide
nanoparticles (IONPs) exhibit a saturation magnetization (Ms) of 78 emu·g−1IONPs, but, as expected,
the magnetic susceptibilities of the GbMNPs suffer a decrease with the increase of the graphene-based
shell thickness to 69.8 and 61.2 emu·g−1IONPs, respectively for GbMNP-2 and GbMNP-3. The high
Ms found on these GbMNPs can be attributed to the presence of small clusters of superparamagnetic
magnetite, as suggested by the TEM images. Remarkably, the superparamagnetic-like behaviour
of the GbMNPs was maintained, as shown by the low-field data (inset in Figure 4, and Table 3),
where saturation remanence (Mr) and low coercivity (Hc) are negligible.
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Table 3. The magnetic properties of the uncoated IONPs and as-synthesized GbMNPs: saturation
magnetization (Ms), coercivity (Hc), and saturation remanence (Mr).
Sample Ms (emu·g−1 IONPs) Hc (Oe) Mr (emu·g−1 IONPs)
IONPs 77.7 18.33 1.94
GbMNP-2 69.8 3.54 1.16
GbMNP-3 61.2 41.33 5.08
3.2. DOX Loading Studies
Doxorubicin (DOX) is one of the chemotherapeutic drugs most commonly used [38], however, it
presents several lethal side effects [39]. One of the strategies to overcome this toxicity issue is through
targeted drug delivery. For this purpose, DOX was chosen to study the drug delivery properties of the
developed GbMNPs. To assess the DOX loading and release, UV-Vis absorbance analysis at 480 nm
was used [40]. The drug loading efficiency and drug loading capacity profiles were evaluated by
ranging the initial DOX concentration between 10 to 300 µg·mL−1, on a fixed amount of GbMNPs
(500 µg·mL−1). The drug loading profiles are shown in Figure 5.
C 2018, 4, x FOR PEER REVIEW  9 of 15 
 
Figure 4. The magnetization curves of (a) IONPs; (b) GbMNP-2 and (c) GbMNP-3. Hysteresis loops 
at 27 °C up to ±20 kOe; the inset corresponds to the zoom in the low field region. 
Table 3. The magnetic properties of the uncoated IONPs and as-synthesized GbMNPs: saturation 
magnetization (Ms), coercivity (Hc), and saturation remanence (Mr). 
Sample Ms (emu·g−1 IONPs) Hc (Oe) Mr (emu·g−1 IONPs) 
IONPs 77.7  18.33 1.94 
GbMNP-2 69.8 3.54 1.16 
GbMNP-3 61.2 41.33 5.08 
. .  oa i  t ies 
i     f t e che otherapeutic drugs most commonly used [38], however, 
it pr sents s veral lethal side effects [39]. One of the strategies to overcome th s toxicity issue is 
th ough targeted drug delivery. For this purpose, DOX was chos n to study the drug delivery 
properti s of the devel ped GbMNPs. To ssess the DOX loading and release, UV-Vi  absorba ce 
an lysis at 480 nm was sed [40]. The drug loading efficiency and drug loading capacity profiles were 
evaluated by ranging the initial DOX concentration between 10 to 300 µg·mL−1, on a fixed amount of 
GbMNPs (500 µg·mL−1). The ru  loading profiles are shown in Figure 5. 
 
Figure 5. The drug loading profiles of GbMNPs at different initial doxorubicin (DOX) concentrations 
(10–300 µg·mL−1). (a) GbMNP-2; (b) GbMNP-3. Error bars represent the standard deviation of 
triplicate drug loading tests. 
In general, it was observed that the drug loading capacity of GbMNPs increases with the increase 
of the initial DOX concentration. A maximum of 301 µg·mg−1 is obtained for GbMNP-2 when the DOX 
concentration in the solution is 250 µg·mL−1, whereas GbMNP-3 reached 216 µg·mg−1 when the DOX 
concentration is 300 µg·mL−1. The estimated loading contents of DOX in these cases were about 1.94 
mg DOX m−2GbMNP-2 and 0.88 mg DOX m−2GbMNP-3. It is interesting to observe that the sample with a higher 
i . e r loa i r files f s at iff r t i iti l r i i ( ) t ti
1). (a) GbMNP-2; (b) GbMNP-3. Error bars represent the standard eviation f
tri li t l i t t .
In general, it was observed that the drug loading capacity of GbMNPs increases with the increase
of the initial DOX concentration. A maximum of 301 µg·mg−1 is obtained for GbMNP-2 when the
DOX concentration in the solution is 250 µg·mL−1, whereas GbMNP-3 reached 216 µg·mg−1 when the
DOX concentration is 300 µg·mL−1. The estimated loading contents of DOX in these cases were about
1.94 mg DOX m−2GbMNP-2 and 0.88 mg DOX m−2GbMNP-3. It is interesting to observe that the sample
with a higher hollow cavity and a larger specific surface area, GbMNP-3, presents a lower drug loading
efficiency (DLE) and drug loading capacity profile. These unexpected results could be explained by
the presence of a thicker graphene layer in the sample GbMNP-3, and the smaller pore sizes of this
graphene-based shell (Figure 2c and Table 2). This combination could result in the fast clogging of the
pores in the outer layers of the graphene shell with the drug molecules, restricting the access of the
DOX molecules to the inner hollow cavity.
Nevertheless, these in vitro drug loading results show the remarkable capability of GbMNPs
to load high contents of DOX. This ability can be attributed to the pi–pi stacking and the possible
presence of carboxylic acid groups, besides the epoxide and hydroxyl groups, on the graphene-based
nanomaterials [41]. Seeking new insights on this phenomenon, the pHPZC, i.e., the pH at which the
surface charge is zero, was determined for the as-synthesized GbMNPs and functionalized GbMNPs.
The pHPZC of the as-synthesized GbMNPs is highly basic (pH ~12), possibly as an effect of the alkaline
etching treatment to remove the silica template. On the other hand, the pHPZC of the functionalized
GbMNPs with HNO3 revealed strong acidic pH values (~2.0), indicating that acidic groups, such as
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carboxylic groups, were, in fact, formed during the chemical treatment. In addition, the pHPZC of
the functionalized GbMNPs allows us to conclude that their surface is negatively charged at the
working pH for the drug delivery tests (pH ~6.0), i.e., pH > pHPZC [42]. On the other hand, at this
working pH, the chemotherapeutic drug DOX is positively charged (pKa ~8.3 [43]). These results
indicate non-covalent interactions, such as electrostatic, between the nanocarriers (GbMNPs) and DOX.
3.3. In Vitro pH-Dependent Drug Release and Kinetics Studies
The exploration of pH differences between a tumour and a normal tissue’s microenvironment
motivates the development of smart nanocarriers designed as drug delivery systems able to be
triggered by acidic pH values [23]. For this purpose, the cumulative pH-dependent DOX release
profiles from the GbMNPs-DOX systems were assessed under different pH values, 7.4, 6.0, and 4.5,
which mimics, respectively, the pH conditions found in healthy tissues, tumour microenvironment
and intracellular tumour endosome/lysosome [23].
Graphene-based nanocarrier samples, GbMNP-2-DOX and GbMNP-3-DOX, show similar shape
drug release profiles (Figure 6a,b, respectively).
C 2018, 4, x FOR PEER REVIEW  10 of 15 
hollow cavity and a larger specific surface area, GbMNP-3, presents a lower drug loading efficiency 
(DLE) and drug loading capacity profile. These unexpected results could be explained by the 
presence of a thicker graphene layer in the sample GbMNP-3, and the smaller pore sizes of this 
graphene-based shell (Figure 2c and Table 2). This combination could result in the fast clogging of 
the pores in the outer layers of the graphene shell with the drug molecules, restricting the access of 
the DOX molecules to the inner hollow cavity. 
Nevertheless, these in vitro drug loading results show the remarkable capability of GbMNPs to 
load high contents of DOX. This ability can be attributed to the π– stacking and the possible 
presence of carboxylic acid groups, besides the epoxide and hydroxyl groups, on the graphene-based 
nanomaterials [41]. Seeking new insights on this phenomenon, the pHPZC, i.e., the pH at which the 
surface charge is zero, was determined for the as-synthesized GbMNPs and functionalized GbMNPs. 
The pHPZC of the as-synthesized GbMNPs is highly basic (pH ~12), possibly as an effect of the alkaline 
etching treatment to remove the silica template. On the other hand, the pHPZC of the functionalized 
GbMNPs with HNO3 revealed strong acidic pH values (~2.0), indicating that acidic groups, such as 
carboxylic groups, were, in fact, formed uring the chemical treatment. In addition, the pHPZC of the 
functio alized GbMNPs allows us to conclude that their surface is negatively charged at the working 
pH for the drug delive y tests (pH ~6.0), i.e., pH > pHPZC [42]. On the other hand, at t is working pH, 
the chemotherapeutic drug DOX is positively charged (pKa ~8.3 [43]). These results indicate non-
covalent interactions, such s electrostatic, b tween he nanocarriers (GbMNPs) and DOX.  
3.3. In Vitro pH-Dependent Drug Release and Kinetics Studies 
The exploration of pH differences between a tu our and a nor al tissue’s icroenviron ent 
motivates the development of smart nanocarriers designed as drug delivery systems able to be 
triggered by acidic p  values [23]. For this purpose, the cu ulative p -dependent DOX release 
profiles fro  the b NPs-DOX systems were assessed under different pH values, 7.4, 6.0, and 4.5, 
hich i ics, respectively, the p  conditions found in healthy tissues, tu our icroenviron ent 
and intracellular tu our endoso e/lysosome [23]. 
Graphene-based nanocarrier samples, Gb NP-2-D X and GbMNP-3-DOX, show similar shape 
drug release profiles (Figure 6a,b, respectively). 
 
Figure 6. The pH-responsive release profiles of doxorubicin (DOX) from GbMNPs under different pH 
values (7.4, 6.0, and 4.5), at 37 °C. (a) GbMNP-2-DOX; (b) GbMNP-3-DOX. Error bars represent the 
standard deviation of triplicate drug release tests. 
Analysis of the first incubation hour reveals that just a very low amount of DOX was released at 
physiological pH conditions (i.e., pH 7.4). At pH 6.0, the drug release was slightly higher than at pH 
7.4, i.e., 15% versus 10% for GbMNP-2-DOX and 7% versus 6% for GbMNP-3-DOX, respectively. 
However, the nanocarriers reveal a remarkable increase of the released DOX (around 30% for sample 
GbMNP-2-DOX and 15% for sample GbMNP-3-DOX) at pH 4.5. For long-period drug release, only 
around 20% of DOX was released by both materials under physiological conditions after 48 h. Under 
Figure 6. The pH-responsive release profiles of doxorubicin (DOX) from GbMNPs under different pH
values (7.4, 6.0, and 4.5), at 37 ◦C. (a) GbMNP-2-DOX; (b) GbMNP-3-DOX. Error bars represent the
standard deviation of triplicate drug release tests.
Analysis of the first incubation hour reveals that just a very low amount of DOX was released
at physiological pH conditions (i.e., pH 7.4). At pH 6.0, the drug release was slightly higher
than at pH 7.4, i.e., 15% versus 10% for GbMNP-2-DOX and 7% versus 6% for GbMNP-3-DOX,
respectively. However, the nanocarriers reveal a remarkable increase of the released DOX (around
30% for sample GbMNP-2-DOX and 15% for sample GbMNP-3-DOX) at pH 4.5. For long-period
drug release, only around 20% of DOX was released by both materials under physiological conditions
after 48 h. Under pH 6.0, sample GbMNP-2-DOX released a maximum of 41% of DOX, whereas sample
GbMNP-3-DOX released around 35% after the same period of time. Under intracellular acidic
pH conditions, and after the initial burst release of up to 30%, sample GbMNP-2-DOX released
a remarkable value of 75% of the encapsulated drug, and sample GbMNP-3-DOX, almost 56%.
The outstanding pH-responsive drug release performance of GO is attributed to the presence of
the pi–pi stacking, as well as electrostatic interactions between the graphene-based nanostructures and
aromatic DOX molecules [23]. Thus, in the presence of mild acidic environment such as the ones found
in tumours, those interactions can be easily disrupted [14] by the increased solubility of DOX caused
by the protonation process [18]. In this study, it was found that the pH-dependent controlled release
phenomenon can be attributed to the loss of the negative surface of the nanocarriers’ surface (GbMNPs),
as the pH of the solutions goes from 7.4 to 4.5, and related to the charge increased protonation [23].
This increase of the surface charge causes a reduction of the electrostatic attraction between the
GbMNPs and DOX protonated molecules, which leads to the increase of the drug release. Overall,
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the in vitro pH-responsive drug release results suggest the great ability to use these nanocarriers as
efficient drug encapsulation systems for local drug release.
The kinetic studies using the drug release data from GbMNPs are listed in Table 4.
The Korsmeyer–Peppas model (with the higher R2 values) was considered the best one to describe
the system. Moreover, the respective n values were below 0.45 in all cases, which means that the drug
release is controlled by simple quasi-Fickian diffusion [23].
Table 4. The in vitro drug release kinetics studies of GbMNPs.
Sample pH Zero-Order First-Order Hixson-Crowell Higuchi Korsmeyer–Peppas
R2 R2 R2 R2 R2 n
GbMNP-2
7.4 0.45 0.37 0.47 0.72 0.85 0.30
6.0 0.46 0.35 0.50 0.73 0.84 0.33
4.5 0.47 0.39 0.58 0.73 0.96 0.44
GbMNP-3
7.4 0.41 0.39 0.43 0.67 0.85 0.23
6.0 0.48 0.37 0.51 0.74 0.85 0.33
4.5 0.40 0.34 0.46 0.66 0.81 0.26
3.4. In Vitro Biocompatibility and Cellular Drug-Delivery Assay
Biocompatibility is a key feature for the potential application of nanomaterials in
biological systems, where an ideal nanocarrier should ensure low or negligible toxicity.
Biocompatibility of GbMNPs at different concentrations (0.12–30.0 µg·mL−1) was determined in
PLP2 cells, and normalized to the cell viability in cell cultures for 48 h, at 37 ◦C.
The biocompatibility tests (Figure 7) reveal a very distinct behaviour between the developed
nanocarriers, GbMNP-2 and GbMNP-3, tested in PLP2 cells. GbMNP-2, characterized by a
few layer GO yolk-shell magnetic nanoparticles, exhibits good biocompatibility even at the high
concentration of 30.0 µg·mL−1. On the other hand, GbMNP-3, characterized as a yolk-shell
magnetic nanostructure coated with a defective multi-graphitic-layer shell, shows a severe cell
inhibition behaviour at high concentrations of nanocarriers. Indeed, these results are in line
with other results reported in the literature, where the cytotoxicity of different graphene-based
nanomaterials has been discussed [44–46]. According to the available information, the lateral size,
shape, number of layers, stiffness, hydrophobicity, surface functionalization, concentration dose,
and chemistry of the graphene-based materials, all play an important role on the interaction of
this type of material with cell membranes, intracellular uptake, and its cytotoxicity [46].C 2018, 4, x FOR PEER REVIEW  12 of 15 
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In addition, the in vitro cellular drug-delivery assays of free DOX and GbMNP-2 carrying DOX
(GbMNP-2-DOX) were investigated in the tumour cell line, MCF-7, and compared with the primary
cell culture cells, PLP2, as shown in Figure 8a,b.
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In both cell lines, MCF7 and PLP2, GbMNP-2-DOX nanocarriers and free DOX exhibit a
dose-dependent cytotoxicity. It was also observed that free DOX shows more toxicity over the cell lines,
especially over the healthy cell line PLP2 than in the DOX released from the nanocarriers at the time
point investigated (48 h). Nevertheless, and in opposition with free DOX, the designed GbMNP-2
nanocarriers show the ability to preferentially deliver the chemotherapeutic drug into the cancer cells.
Therefore, the GbMNP-2 material exhibits remarkable combined characteristics for an efficient
drug delivery, namely, a good loading capacity, high pH-sensitivity, high drug release at the mimic
tumoral pH, high Ms, superparamagnetic behaviour, and biocompatibility.
4. Conclusions
Graphene-based magnetic nanoparticles (GbMNPs) were developed for biomedical applications
by using a simple tailor-made coating protocol. The results show the capability to synthesize GbMNPs
with very distinctive physicochemical and toxicological properties, just by adjusting the number of
carbon precursors. In particular, a hybrid magnetic nanomaterial was developed with exceptional
characteristics (GbMNP-2) to be applied as a drug nanocarrier system. Impressively, this hybrid
nanomaterial exhibited: (i) good colloidal stability in aqueous solutions; (ii) exceptional Ms value
of 69.8 emu·g−1; (iii) superparamagnetic behaviour; (iv) strong pH-triggered drug release response;
and (v) biocompatibility. Additionally, the combination of these parameters also indicates a high
potentiality to couple these magnetic nanocomposites with other biomedical applications, namely,
magnetic hyperthermia and/or magnetic resonance imaging [47,48]. Therefore, the presented strategy
reported in this work shows the potentiality to synthesize tailor-made graphene-based magnetic
materials specially designed for the combined treatment of cancer.
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